Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn’s disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course

INTRODUCTION: Immunomodulators such as thiopurines (azathioprine (AZA)/6-mercaptopurine (6MP)), methotrexate (MTX) and biologics such as adalimumab (ADA) are well established for maintenance of remission within paediatric Crohn’s disease (CD). It remains unclear, however, which maintenance medicatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, Rachel E, Aloi, Marina, de Ridder, Lissy, Croft, Nicholas M, Koletzko, Sibylle, Levine, Arie, Turner, Dan, Veereman, Gigi, Neyt, Mattias, Bigot, Laetitia, Ruemmele, Frank M, Russell, Richard K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Gastroenterology and Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332179/
https://www.ncbi.nlm.nih.gov/pubmed/32611737
http://dx.doi.org/10.1136/bmjopen-2019-034892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332179/
https://www.ncbi.nlm.nih.gov/pubmed/32611737
http://dx.doi.org/10.1136/bmjopen-2019-034892

Ejemplares similares